Article

25 Things About Me

Author(s):

Linnea Olson

I have stage 4 lung cancer. Here are 24 other things about me.

  1. I have stage 4 lung cancer; the histology is invasive mucinous adenocarcinoma.
  2. I was diagnosed when I was 45 years old.
  3. The youngest of my three children was seven.
  4. That was 10 years ago — it will be 11 years in April (woohoo!)
  5. My first line of treatment was a lower left lobectomy followed by four rounds of adjuvant chemotherapy.
  6. Staged at 1b initially, I was hoping I’d be cured.
  7. My cancer came back almost immediately.
  8. For two years, we watched and waited as there were no other viable treatments.
  9. By June 2008, I had more than 33 tumors in my lungs and a biopsy confirmed metastatic spread.
  10. I was told I had three to five months to live.
  11. This was one week before my daughter got married.
  12. Even though EGFR-negative, I started Tarceva (erlotinib) as a last ditch effort and began to say goodbye to family.
  13. At a scan review in September, it was clear that my cancer was spreading but there was good news.
  14. My biopsy showed that I was ALK-positive and a phase 1 trial targeting ALK mutations had just opened.
  15. On October 1, 2008, I became the fourth person in the world with NSCLC to take Xalkori (crizotinib).
  16. I felt better within days of regular dosing.
  17. My scan review six weeks later showed almost complete resolution of the cancer in my lungs.
  18. I took Xalkori for three years before progression forced me to switch therapies.
  19. I enrolled on another phase 1 clinical trial for Zykadia (ceritinib/LDK378) with similar results.
  20. This time, I got 18 months out of an experimental therapy.
  21. When I came off trial, I returned to chemotherapy again for six months and then I took a break.
  22. I went almost a year without treatment (glorious!) but I was also becoming more symptomatic.
  23. In May 2014, I enrolled into my third phase 1 clinical trial for PF-006463922/lorlatinib — once again I responded.
  24. My cancer has been stable for 18 months and I feel fabulous.
  25. I can’t wait to share more of my story with the readers of CURE!

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Related Content
Image of woman.
July 18th 2025

What Makes a Quality Cancer Support Group?

Sue McCarthy
After attending several cancer support groups, I reflect on what makes them helpful, inclusive and healing — and invite others to share their insights too.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Jane Biehl is a 12-year survivor of a very rare form of blood cancer, known as myelodysplastic syndrome (MDS). Catch up on all of Jane’s blogs here!
July 18th 2025

Max The Butterfly: Hope and Resurrection After Cancer

Jane Biehl Ph.D.
Butterflies are believed to be a symbol of resurrection and hope. This is an inspiring story about this phenomenon.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
FDA grants priority review to TAR-200 for high-risk bladder cancer unresponsive to BCG: © stock.adobe.com.
July 18th 2025

FDA Grants Priority Review to TAR-200 for Bladder Cancer Subset

Spencer Feldman
FDA grants priority review to TAR-200, which demonstrated an 82% complete response in high-risk bladder cancer unresponsive to Bacillus Calmette-Guérin.
Image of Karen.
July 17th 2025

What’s in a Name? How I Chose ‘Person’ Over ‘Survivor’ After Cancer

Karen Cohn
When asked to choose a word other than “survivor” to describe myself, I chose “person” because cancer does not define who I am.